PFIZER INC Business Combination, Contingent Consideration, Liability, Noncurrent
PFIZER INC (PFE) had Business Combination, Contingent Consideration, Liability, Noncurrent of $2.16 billion as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent · last filed 2026-08-04
- 2026-06-28: Business Combination, Contingent Consideration, Liability, Noncurrent $2.16B.
- 2026-03-29: Business Combination, Contingent Consideration, Liability, Noncurrent $1.95B.
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Noncurrent $1.70B.
- 2024-12-31: Business Combination, Contingent Consideration, Liability, Noncurrent $477.00M.
| Period end | Business Combination, Contingent Consideration, Liability, Noncurrent |
|---|---|
| 2026-06-28 | $2.16B 10-Q · filed 2026-08-04 |
| 2026-03-29 | $1.95B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $1.70B 10-Q · filed 2026-08-04 |
| 2024-12-31 | $477.00M 10-K · filed 2026-02-26 |
| 2023-12-31 | $512.00M 10-K · filed 2025-02-27 |
| 2022-12-31 | $603.00M 10-K · filed 2024-02-22 |
| 2021-12-31 | $563.00M 10-K · filed 2023-02-23 |
| 2020-12-31 | $566.00M 10-K · filed 2022-02-24 |
| 2020-09-27 | $576.00M 10-Q · filed 2020-11-05 |
| 2020-06-28 | $570.00M 10-Q · filed 2020-08-06 |
| 2020-03-29 | $544.00M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $551.00M 10-K · filed 2021-02-25 |
| 2018-12-31 | $708.00M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |